Disease relevance of Flerobuterol

• Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia [1].

Psychiatry related information on Flerobuterol

• Given the long-standing notion that the serotonergic (5-HT) system might be involved in the etiology and/or the therapeutics of affective disorders and that this class of adrenergic agents can alter factors regulating 5-HT transmission, the effects of acute and repeated administrations of flerobuterol on the 5-HT system were studied [2].
• Salbutamol and flerobuterol decreased locomotor activity [1].

High impact information on Flerobuterol

• The influence of 2- and 14-day treatments with flerobuterol, a preferential beta(2)-adrenoceptor agonist, on regional serotonin (5-HT) synthesis in the rat brain was studied by autoradiography using alpha-[(14)C]methyl-L-tryptophan [3].
• Flerobuterol was delivered at a rate of 0.5 mg/kg/day using osmotic pumps implanted s.c. The 2-day flerobuterol treatment significantly increased plasma Trp, both free and total, and decreased plasma Leu and Ile [3].
• Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia [1].
• All agonists stimulated cyclic AMP accumulation in the cerebral cortex but flerobuterol was inactive in the cerebellum [4].

Analytical, diagnostic and therapeutic context of Flerobuterol

• Flerobuterol, a new beta-adrenoceptor agonist, exhibits antidepressant activity in animal models [2].

References